Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial
- DOI
- 10.1016/j.breast.2026.104894
- Published
- 2026-10
- Container
- The Breast
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.breast.2026.104894,
title = {Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial},
author = {Frédérique Penault-Llorca and Amelie Lusque and Thomas Filleron and Kevin Tran and Lili Du and Rick Baehner and Florence Dalenc and Magali Lacroix-Triki and Thomas Bachelot and Fabrice Andre and Pascal Boucher and Jérôme Lemonnier and W. Fraser Symmans},
year = {2026},
journal = {The Breast},
doi = {10.1016/j.breast.2026.104894},
url = {https://doi.org/10.1016/j.breast.2026.104894}
}RIS
TY - JOUR TI - Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial AU - Frédérique Penault-Llorca AU - Amelie Lusque AU - Thomas Filleron AU - Kevin Tran AU - Lili Du AU - Rick Baehner AU - Florence Dalenc AU - Magali Lacroix-Triki AU - Thomas Bachelot AU - Fabrice Andre AU - Pascal Boucher AU - Jérôme Lemonnier AU - W. Fraser Symmans PY - 2026 JO - The Breast DO - 10.1016/j.breast.2026.104894 UR - https://doi.org/10.1016/j.breast.2026.104894 ER -
APA
Penault-Llorca, F., Lusque, A., Filleron, T., Tran, K., Du, L., Baehner, R., Dalenc, F., Lacroix-Triki, M., Bachelot, T., Andre, F., Boucher, P., Lemonnier, J., & Symmans, W. F. (2026). Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial. The Breast. https://doi.org/10.1016/j.breast.2026.104894
Source records
- crossref · retrieved 2026-09-27T16:29:54.064Z